CN1382796A - Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it - Google Patents
Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it Download PDFInfo
- Publication number
- CN1382796A CN1382796A CN 01112773 CN01112773A CN1382796A CN 1382796 A CN1382796 A CN 1382796A CN 01112773 CN01112773 CN 01112773 CN 01112773 A CN01112773 A CN 01112773A CN 1382796 A CN1382796 A CN 1382796A
- Authority
- CN
- China
- Prior art keywords
- inosine triphosphate
- polypeptide
- human
- human inosine
- triphosphate pyrophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A novel polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34, the pharmaceutical compound containing it, the method for applying the said polypeptide to treat diseases such as development disorder, monster, tumor, infection, etc, the antagon of the said polypeptide and its medical action, and the application of the said polynucleotide are disclosed.
Description
The invention belongs to biological field, described a kind of human inosine triphosphate pyrophosphate hydrolase-21.34 of pure biologically active and had the pharmaceutical compound of this human inosine triphosphate pyrophosphate hydrolase.
Inosine triphosphate (ITP) exists in the various cells of organism widely with deoxyinosine triphosphate (dITP) (dITP).Inosine triphosphate and deoxyinosine triphosphate (dITP) are formed through pyrophosphorylation or substep phosphorylation by the compound t-inosinic acid of purine biosynthetic metabolism usually.T-inosinic acid is the important metabolic substd of purine compound synthetic, also is significant energy metabolic substd AMP and GMP synthetic important as precursors in the organism.Hence one can see that, and inosine triphosphate synthetic and metabolic disturbance in vivo will cause the unusual of the interior correlation energy pathways metabolism of body, and then cause various relevant energy metabolism and substance metabolism disorder disease.
Inosine triphosphate pyrophosphate hydrolase also is a kind of common lytic enzyme in the organism, and it is the hydrolysis reaction of catalysis inosine triphosphate and deoxyinosine triphosphate (dITP) in vivo, makes it to be decomposed into inosine diphosphate and t-inosinic acid.The sudden change of this enzyme or abnormal expression will cause the unusual of interior correlation energy of body and substance metabolism approach equally, and then cause various relevant diseases.
Polypeptide of the present invention is a kind of new human inosine triphosphate pyrophosphate hydrolase, catalysis inosine triphosphate and deoxyinosine triphosphate (dITP) are hydrolyzed to t-inosinic acid and phosphoric acid in vivo by this enzyme of enzyme activity assay experiment confirm, and whether its action activity is strong and weak reaches the big or small directly related of pH value with the existence of magnesium ion, and very low to other purine nucleotides triphosphoric acid substrate catalytic activity.Hence one can see that, and it is a kind of new human inosine triphosphate pyrophosphate hydrolase-21.34.Its sudden change or abnormal expression will cause the unusual of interior correlation energy of body and substance metabolism approach, and then cause various relevant diseases.
Because human inosine triphosphate pyrophosphate hydrolase-21.34 albumen plays an important role in regulating body critical functions such as cell fission and fetal development as mentioned above, this albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative.
Another object of the present invention provides the method for production human inosine triphosphate pyrophosphate hydrolase-21.34.
Another object of the present invention provides the method for purifying human inosine triphosphate pyrophosphate hydrolase-21.34.
Another object of the present invention has provided at the simulated compound of polypeptide-human inosine triphosphate pyrophosphate hydrolase-21.34 of the present invention, antagonist, agonist, inhibitor.
Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with human inosine triphosphate pyrophosphate hydrolase-21.34.
The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.
The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of the growth disorder in preparation, monster, tumour, infection and nervous system disorders or other are because the purposes of the medicine of human inosine triphosphate pyrophosphate hydrolase-21.34 disease that abnormal expression causes.
The present invention relates to the enriched material of suspension, not long ago this enriched material was transformed into floating outstanding preparation in administration according to the present invention.
These enriched materials can have various compositions.The present invention also comprises the further combination between needed solvent of concentrated solution and/or suspension agent and dilution or the solution, has obtained suspension agent of the present invention thus.
The present invention also relates to the combination of other manifestation or various manifestation, all these have finally all caused injection liquid of the present invention.
The following term of using in this specification sheets and claims has following implication unless stated otherwise:
" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.
" antagonist " or " inhibition " is meant when combining with human inosine triphosphate pyrophosphate hydrolase-21.34, a kind of sealing or the biologic activity of mediator's inosine triphosphate pyrophosphate hydrolase-21.34 or the molecule of immunologic competence.Antagonist and inhibition can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of human inosine triphosphate pyrophosphate hydrolase-21.34.
" agonist " is meant when combining with human inosine triphosphate pyrophosphate hydrolase-21.34, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of human inosine triphosphate pyrophosphate hydrolase-21.34.
The order of purification step of the present invention is: cationic exchange, affinity chromatography, ultrafiltration, gel infiltration (adding the ultrafiltration of reclaiming component) and anionresin.
Behind this purification process, usefulness all be conventional art.For the purpose of storing or handling, product just should be by freeze-drying.Product concentrates for influencing, suitable step stable or other process is ripe for other.
Can be with enzyme of the present invention and stand-in, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Human inosine triphosphate pyrophosphate hydrolase-21.34 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to patient's human inosine triphosphate pyrophosphate hydrolase-21.34 will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Human inosine triphosphate pyrophosphate hydrolase-21.34 can add application with water and/or oily injection, or uses as the salt with certain acid or alkali formation.With the form of prodrug, ester for example, it also is possible being applied.
During as injection, except water, the aqeous suspension of intramuscular injection also can contain liquid excipient, for example, and ethanol, glycerine, propylene glycol, polyoxyethylene glycol, triglycol.The buffered soln of various materials such as phosphoric acid salt, Citrate trianion, Tutofusin tris, ascorbate salt, acetate, succinate, tartrate, glyconic acid and Lactated damping fluid all can be used for regulating pH value makes it the usefulness of (approximately PH7.4) or conduct buffering within physiological range as far as possible.The PH of aqueous solution preparation of the present invention is 4.5-8.5, preferably 6.5-7.5.The osmolality of aqeous suspension (osmolality) is 200-900mosmol/kg, 260-390mosmol/kg preferably, and can be adjusted to a suitable grade and ooze condition by adding the mixture of sodium-chlor, glucose, fructose, glycerine, sorbyl alcohol, mannitol, sucrose, Xylitol or these materials.
In addition, can also use some other prescription reagent, for example thickening agents is (as methylcellulose gum, Natvosol, hydroxypropylcellulose, Xylo-Mucine, polyvinylpyrrolidone, gelatin etc.), sorbent material, the screening agent of light, the absorption inhibitor, the crystallization retarding agent, complexing agent (as, NaEDTA, phosphoric acid salt, nitrate, acetate, Citrate trianion and other salt) antioxidant (xitix, sulfite compound, the L-halfcystine, sulfurous base dipropionic acid, thiolactic acid, Dan Shudai glycerine, propyl propionate (propyl gall-ate) etc.), sanitas (PHB ester, phenol and derivative thereof, organomercury compound, butylene-chlorohydrin, phenylcarbinol, ethanol, 1,3 butylene glycol, benzalkonium chlorideChlorhexidline salts, phenylformic acid and salt thereof, Sorbic Acid and other).If suitable, local anesthetic, like that such as picture ethocaine, lidocaine hydrochloride, can add in the aqeous suspension.
When the preparation aqeous suspension, the size of necessary protection granules is at 0.5-150 μ m.Be in particular 4-40 μ m.Can realize the sustained release of active substance by the different size particles of control mixed active material from intramuscular suspension storehouse.
For the situation of aqeous suspension, 90% particulate size is preferably in 10-20 μ m.The sticking 5-500mPas that encourages of aqeous suspension, preferably 10-130mPas.
The aqeous suspension of human inosine triphosphate pyrophosphate hydrolase-21.34 can adopt the diverse ways preparation.A kind of method is that certain gyrase inhibitor active compound is added in the water figuration medium with particulate form, comprises the auxiliary of having mentioned certainly; When adopting this technology, should strict guarantee can not make the crystalline growth exceed above-mentioned boundary.In some cases, active compound must be made into the form of its a kind of stable hydrate earlier, and then further is processed into a kind of suspension.If last sterilization should not be used heating method, so good must under aseptic condition, carrying out, the active compound of use and auxiliary material will pass through pre-treatment.At last, it is feasible adopting the radiation sterilization mode.
The aqeous suspension of human inosine triphosphate pyrophosphate hydrolase-21.34 can also be prepared by control sedimentary method from solution.For example, it is feasible active compound being dissolved in the acid that can tolerate on certain physiology.These acid comprise hydrochloric acid, methylsulfonic acid, propionic acid, succsinic acid, pentanedioic acid, citric acid, fumaric acid, toxilic acid, tartrate, L-glutamic acid, glyconic acid, glucuronic acid, galacturonic acid, xitix, phosphoric acid, hexanodioic acid, hydroxyethanoic acid, sulfuric acid, nitric acid, acetate, oxysuccinic acid, L-aspartic acid, lactic acid, isethionic acid, lactobionic acid and oxalic acid or each seed amino acid, as L-arginine, L-aspartic acid, L-half Guang ammonia, L-L-glutamic acid, glycine, L-leucine, L-Methionin and L-Serine, can slowly be warmed to 20-80 ℃ if desired
Normally used acid is excessive, for example, and according to the regulation of european patent application 86114131.5 and 84110474.8.Then, add the alkaline solution that can tolerate on a kind of physiology of people and regulate PH to 7 (physiology PH), alkaline solution is just like sodium hydroxide, potassium hydroxide or Mai Geluming (meglumine), and last active compound is precipitated out from solution.On the other hand, also human inosine triphosphate pyrophosphate hydrolase-21.34 active compound can be dissolved in the alkaline medium of aforementioned a kind of alkali, aforesaid then a kind of acid is precipitated out it.
Yet bronsted lowry acids and bases bronsted lowry solution can merge in not pressurization situation, also can pressurize, and pressure range is 2 to 100 crust.Control in the suspension by qualifications that to form granular size be possible.Actual precipitation operation also can be used high speed agitator, the homogenizer of rotation-fixedly, and high-pressure homogenizer (100-1000 crust) and other similar approach are to help homogenizing.If because may make particle grow up and can not in the end sterilize, can be in prepare suspension under the aseptic condition, the component that is about to sterilization in advance and carries out the bronsted lowry acids and bases bronsted lowry of sterile filtration under the strict sterilising conditions of another kind is mixed under aseptic condition.Sometimes sanitas or its binding substances that can application of aforementioned add a suitable dosage to protect aseptic making.Last sterilization also can have been used the mode of gamma-radiation sterilization.
In addition, also have a kind of form to provide, the active compound that promptly this preparation contains is done, and does not have liquid excipient.The liquid excipient of packing just before administration the solid ingredient in interim and the prescription mix mutually, in this case must shake well with the uniform distribution of assurance solid particulate in liquid phase.
Above-mentioned and below various muscle Wang of discussing penetrate in the preparation, oleaginous base contains water-soluble, crystallization or unbodied active compound, for example with the hydrochloride lactic acid salt, the dish hydrochlorate, to a tosylate or other and the good sour formed salt of physiological tolerance, intramuscular injection based on oleaginous base also can contain surfactant, for example be soybean lecithin, egg lecithin, the various Yelkin TTS of brain Yelkin TTS or rape Yelkin TTS form or the good tensio-active agent of other physiological tolerances, its concentration is 0.1-30%, 0.2-10% particularly, especially 5.5-5.5%W/V, the intramuscularly agent of oleaginous base is except the water-soluble salt that contains active compound, also contain the acid that can tolerate on the excessive physiology, as lactic acid or citric acid, its scope is 1-300mmol/L, particularly 5-50mmol/L, preferably 10-30mmol/L.The intramuscularly agent of this oleaginous base is the most special purpose of the present invention.
The contained active compound of the oleagenous suspension of human inosine triphosphate pyrophosphate hydrolase-21.34 is to exist with the form of inner salt or the form of water-soluble salt.
Oleagenous suspension can contain non-water vehicle, such as Witepsol W-S 55 of Prunus amygdalus oil, peanut oil, sweet oil, poppyseed oil, sesame oil, oleum gossypii seminis, soya-bean oil, Semen Maydis oil, Viscotrol C, ethyl oleate, Oleyl oleate, isopropyl myristate, Wickenol 111, medium chain etc.
Can merge Diethylene Glycol and triethylene glycol, the polyoxyethylene of Pluronic type and interpolymer, polyoxy fatty acid esters of sorbitan, fatty acid esters of sorbitan, glyceraloleate, Cremophor EL , imwitor742 and different types of Yelkin TTS such as soybean lecithin, egg lecithin, brain Yelkin TTS and the rape Yelkin TTS etc. of polyoxypropylene that other vehicle that uses also has ethanol, glycerine, propylene glycol, polyoxyethylene glycol, 1,3 butylene glycol, phenylcarbinol, various sources with mentioned material.
What be used as oxidation inhibitor has a-, p-, Y-and 6-vitamin-E, palmitinic acid xitix fat, ascorbyl stearate, L-halfcystine, sulfurous base dipropionic acid, thiolactic acid, Thiovanic acid, first thioglycerin, propyl propionate, butylated hydroxy anisole, butylhydroxy toluene and other.
Sometimes, certain requires viscosity can add portrait ethanol or phenylcarbinol thinner and resemble the aluminum stearate thickening material to obtain.Because the increase of absorption is so can add some acid.The viscosity number of oil-suspending agent is 5-500mPaS, preferably 10-15Pas
The preparation of oil-suspending agent is to be undertaken by the oiliness excipient is mixed with active compound mutually with the auxiliary material that is wherein comprised, and active compound is ground into desired along grain size (referring to the front) and with the mixture homogenize in advance with suitable instrument.90% granular size is 0.5-150 μ m.4-12 μ m in the time of preferably.If can not sterilize at last in discharging container because the granular size of active compound may change, suspension agent must be made under aseptic condition so.Also indicated simultaneously the sterile filtration method of the oil phase that contains suitable dissolved auxiliary material, for example by heat treated to the active compound pre-treatment of sterilizing.Last sterilization also can be used the Y-gamma ray sterilization except the suspension agent that performs, and a kind of fresh preparation of not long ago making in administration can also be provided.In this case, active compound must can be suspended in the liquid excipient in a short period of time when the container of preparation is equipped with in jolting uniformly.
The container that is used to load suspension, active compound, solvent and other manifestation such as suspension-concentrates can be with glass or plastic production.The material of container can contain some material herein, and these materials can play special provide protection for content, such as lucifuge or isolated with oxygen.To small volume container, suspension wherein at this, also can be made injecting systems to these containers being drawn into before the administration among the syringe.
Various injection of the present invention all is applied to the treatment of human body or animal body.
Provide the example of some diseases below, the enough compound preventions of the present invention of energy, the various diseases (including but not limited to) of alleviating or curing:
Grow that disorders such as spina bifida, cranium fissure, anencephalia, brain bulging, hole deformity of brain, congenital hydrocephalus, aqueduct deformity, achondroplastic dwarf's disease, spondyloepiphyseal dysplasia disease, hypogenitalism, epispadia, cryptorchidism, congenital glaucoma or cataract, congenital little fissura palpebrae, retinal development are unusual, atrophia nervi optici congenita, ulcuscuris, monster, Williams syndromes, Alagille syndromes, Bei Wei two syndromes etc.;
Tumour such as substrate epithelial tumor, squama shape epithelial tumor, mucinous tumors, fibroma, lipoma, chondroma, vascular tumor, lymphoma, hemopoietic tissue tumour, neuroma, adenoma etc.;
Infect as furuncle, carbuncle, wound suppuration, pneumonia, meningitis, endocarditis, pseudomembranous enterocolitis, septicemia,
Scald sample skin syndromes, toxic shock syndrome, influenza, measles, the measles bronchitis,
Pneumonia, otitis media, subacute sclerosis surname panencephalitis, mumps, meningitis, pancreatitis,
The treating child asthma bronchiolitis, rubella etc.;
Nervous function is disorderly to comprise inhibition sensory disturbance (anesthesia, feel to go down) as sensory disturbance, pungency sensory disturbance (oxypathy, paresthesia, pain) etc., dyskinesia comprises central paralysis (monoplegia, hemiplegia, paraplegia), lower motor neuron paralysis etc., vegetative nerve (sympathetic and parasympathetic) dysfunction such as the rhythm of the heart is not normal, enteroplegia, biliary colic, raynaud's disease, pulmonary edema etc.
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human inosine triphosphate pyrophosphate hydrolase-21.34.21kDa is proteinic molecular weight.The arrow indication is isolated protein band.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.
Embodiment 1: the clone of human inosine triphosphate pyrophosphate hydrolase-21.34
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone ITPA is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of ITPA clone is 1085bp (shown in Seq ID NO:1), from 105bp to 689bp the open reading frame (ORF) of a 585bp, the new protein (shown in Seq IDNO:2) of encoding arranged.We are with this clone's called after pBS-ITPA, encoded protein matter called after human inosine triphosphate pyrophosphate hydrolase-21.34.Embodiment 2: with the gene of RT-PCR method clones coding human inosine triphosphate pyrophosphate hydrolase-21.34
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5’-CCTGGCCGGAAACTGAGCCGTTCA-3’?(SEQ?ID?NO：3)
Primer2：5’-TTTTTTTTTTTTTCGGAACAGATA-3’?(SEQ?ID?NO：4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-1085bp shown in the SEQ ID NO:1 are identical.Embodiment 3: the vivoexpression of recombinant human inosine triphosphate pyrophosphate hydrolase-21.34, separation and purifying
According to SEQ ID NO:1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5’-CCCCATATGATGGCGGCCTCATTGGTGGGGAAG-3’(Seq?ID?No：5)
Primer4：5’-CATGGATCCTCAAGCTGCCAAACTGCCAAAGTA-3’(Seq?ID?No：6)
5 ' end of these two sections primers contains NdeI and BamHI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NdeI and BamHI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-ITPA plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-ITPA plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NdeI and BamHI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-ITPA) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (NoVagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-ITPA) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant, with carrying out chromatography, obtained the target protein human inosine triphosphate pyrophosphate hydrolase-21.34 of purifying with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product).Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 1) at the 21kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.
Embodiment 4: the purifying human inosine triphosphate pyrophosphate hydrolase-21.34 according to the present invention
Prepare or adjust the concentrated solution (centrat) of fermented product, or impure human inosine triphosphate pyrophosphate hydrolase-21.34 solution in other any source (as serum) prevents the multimerization (by adding just rate acid) and the protease activity (yeast that does not contain the proteolytic enzyme of infringement level by heating or selection) of human inosine triphosphate pyrophosphate hydrolase-21.34 simultaneously so that carry out chromatography with cationic exchange matrix.Preferably add Sodium octoate (chromatographic solution 13 (CS13)-table 2) to final concentration 1-10mM, for example about 5mM is with stabilizes inosine triphosphate pyrophosphate hydrolase-21.34.Transfer pH to 4.3-4.8 with acetate (CS09), be preferably 4.5 ± 0.1 be most preferably ± 0.05), specific conductivity detects should be less than 5.5smScm
-1
The culture supernatant that derives from some host strain or kind contains the proteolytic enzyme of the recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34 of degrading in subsequent process.In this case; This protease activities can by to the culture supernatant heat treated that contains recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34 to destroy.Usually the 1-10mM Sodium octoate is enough to prevent the proteic thermally denature of recombinant human, is enough to make the proteolytic enzyme inactivation under 60-80 ℃ temperature in 30 seconds to 10 minutes.Subsequently; Supernatant can further be regulated as previously mentioned.If there is no the Degradation of proteolytic enzyme is preferably omitted thermal treatment.
Chromatography: all operations all at room temperature (20 ± 0 ℃) carry out.The applied sample amount of human inosine triphosphate pyrophosphate hydrolase in the chromatography column-21.34 (g human inosine triphosphate pyrophosphate hydrolase-21.34/L matrix) depends on SDS-PAGE (under the situation of SP-FF post) or definite human inosine triphosphate pyrophosphate hydrolase-21.34 titre (g/L) of GP-HPLC (to all other posts).The process of each step can be with the uv-absorbing that connects machine, as 254 or 280nm measure and monitor.
The use of cation radical matter makes most of lower molecular weight coloring matter that obtains from yeast fermentation directly by pillar in the first step purification step, and those also are the weak salt washings removals that combines and can use such as the high ionic strength of 1M sodium-chlor with the matrix bonded.Therefore; Do not resemble anionic substrates, it irreversibly adsorbs that class material; Positively charged ion matrix is renewable and be used for the repeatedly circulation of the chromatography of the purifying the first step.Thereby this step has formed the basis of durable commercial chromatography method.
Using the blue type post of Cibacron in the present embodiment removes a kind of because its physicochemical characteristic as the first step purifying for being used to specifically; Human inosine triphosphate pyrophosphate hydrolase-21.34 fragment that is difficult to from human inosine triphosphate pyrophosphate hydrolase-21.34 45KDa of removal as size and iso-electric point is novel.This fragment can combine with dyestuff more strongly than the human inosine triphosphate pyrophosphate hydrolase-21.34 of total length surprisingly, thereby they can be separated.
Used chromatographic solution is listed in the table 1 in detail in human inosine triphosphate pyrophosphate hydrolase-21.34 purifying.Because in human inosine triphosphate pyrophosphate hydrolase-21.34 purifying, use in a large number, and relatively inexpensive, the sort buffer salts solution provides highly purified form and is generally used for comparing cheapness as TriS, HEPES or MOPS and being suitable for present method most of damping fluid with other because of it is industrial.But listed in other the damping fluid substitution list 2, as the damping fluid of close pKa value (as oxysuccinic acid to acetate), but in most of the cases, price is as having got rid of their application in suitability on a large scale.Its solubility is depended in the use of other salt form, can industrially provide and low price.Yet, comprise in CS06 and CS10 post that the tetraborate ion has special benefit because it is compound with macromolecular carbohydrate part and it has been combined closely with the anionic group in the matrix act on especially.This result can increase the purity of human inosine triphosphate pyrophosphate hydrolase in the elutriant-21.34.
Chromatography can use axial-flow type post (axial flow columns), and is the sort of as what provided by Pharmacia, or radial-flow post (radial flow columns), the sort of as what provided by Sepragen.In the present embodiment, used pillar all is an axial-flow type.
Buffered soln can be gripped preparation by following concentration; Perhaps prepare spissated stock solution, instant mixed or dilution during use.
Table 1 is used for the chromatography solution of the human inosine triphosphate pyrophosphate hydrolase-21.34 of purifying embodiment
| Solution | Composition | Concentration (g/L -1) | ????PH | Specific conductivity (mSm -1) | |
| ??CS01 | The steady liquid of SP-EF | ????CH 3COONa.3H 2O ????CH 3COOH (ice) | ??3.69 ??0.220 | ????5.45-5.65 | ??1.9-2.2 |
| ??CS02 | The SP-EF elutriant | ????CH 3COONa.3H 2O ????CH 3COOH (ice) | ??13.6 ??0.750 | ????5.45-5.65 | ??6.5-7.5 |
| ??CS03 | The DBA elutriant | ????NaCl ????CH3COONH4 ????NaOH | ??117 ??3.84 ??0.680 | ????9.0-9.4 | ??125-165 |
| ??CS04 | ????0.5MNaOH | ????NaOH | ??20.0 | ????＞12 | ??80-120 |
| ??CS05 | Gel infiltration | ????CH 3COONa.3H 2O ????CH 3The sad NaOH of COOH (ice) | ??4.94 ??0.380 ??0.721 ??0.190 | ????5.4-5.6 | ??2.9-3.3 |
| ??CS06 | The DE-EF elutriant | ????Na 2B 4O 7.10H 2O ????NACl | ??7.62 ??5.84 | ????8.9-9.3 | ??11.7-13.5 |
| ??CS07 | ????20mMNaOH | ????NaOH | ??0.800 | ????＞12 | ??3.5-5.5 |
| ??CS08 | The DE-FF balance liquid | ????CH 3COONa.3H 2O ????CH 3The sad NaOH of COOH (ice) | ??4.94 ??0.38 ??0.721 ??0.190 | ????5.4-5.6 | ??2.9-3.3 |
| ??CS09 | Acetate | ????CH 3COOH | ??Clacial | ||
| ??CS10 | The DE-FF washings | ????Na 2B 4O 7.10H 2O | ??7.62 | ????9.0-9.4 | ???2.3-2.9 |
| ??CS11 | DE-FF pre-equilibration liquid | ????CH 3COONa.3H 2O ????CH 3COOH (ice) | ??61.8 ??2.98 | ????5.5-5.7 | ???24-28 |
| ??CS12 | DBS balance liquid/washings | ????NaCl ????CH 3COONH 4????NaOH | ??11.7 ??0.960 ??0.150 | ????8.8-9.2 | ???18-22 |
| ??CS13 | The 2M Sodium octoate | Sad NaOH | ??288 ??76.0 | ????7.7-8.2 | |
| ??CS14 | 1.73M phosphoric acid | ????H 3PO 4(85％(w/w)) | ??200 | ????＜1.2 | |
| ??CS15 | 2M ammonia | ????NH 4OH ????(30％NH 3(w/w)) | ??113ml | ||
Cation-exchange chromatography: human inosine triphosphate pyrophosphate hydrolase-the 21.34th, use cation-exchange chromatography, from being Yeast protein (if human inosine triphosphate pyrophosphate hydrolase-the 21.34th derives from yeast-leavened recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34) and other antigen at least, purifying is with concentrated in low molecular weight impurities and the dye compound.What present method adopted is commercial cationic exchange matrix, as SP-agarose FF, and SP-spherosil (Spenerosil), CM-agarose FF, CM-Mierocrystalline cellulose, SE-Mierocrystalline cellulose or S-dextrane gel.Preferred matrix is SP-agarose FF (Pharmacia) height of bed 5-25cm, is preferably 10-15cm, and present embodiment is 12.scm, and the applied sample amount of post is 10 to 50g human inosine triphosphate pyrophosphate hydrolases-21.34/L matrix; Be preferably 40 ± 10g human inosine triphosphate pyrophosphate hydrolase-21.34/L matrix.To remove alkaline stock solution, damping fluid preferably answers the enough surge capabilities of tool to reduce ph is used for removing post to about pH6.0, as the damping fluid of CS01 CS07 stock solution to matrix with the damping fluid balance; Yet any PH little 10 can use in 6.0 damping fluid.When about 6 pairs of the pH value of post effluent liquid, can be judged as balance and finish.
The concentrated solution of adjusting (centrate) adds chromatography column with certain flow rate, for example with 1.0-8.0cm/min; Be preferably 4.0-7.0cm/min, present embodiment is 6.36cm/min, then with a kind of solution washing pillar to remove remaining impurities.This washing soln should be PH＜6.0 and specific conductivity 15 is lower than 5mScm
-1'; Be preferably lower than 3mScm
-1In case human inosine triphosphate pyrophosphate hydrolase-21.34 is by wash-out.Suitable solution is CS01.The step of front is all carried out with the flow rate of 6.36cm/min; Reduce to 0.5-5cm/min for wash-out and all step flow rates subsequently, be preferably 2.0-4.0c./min.Present embodiment is 3.18cm/min, incites somebody to action wash-out human inosine triphosphate pyrophosphate hydrolase-21.34 effectively with the volume, the increase ionic strength that reduce wash-out; Use conductivity range at 5-10mscm
-1Solution, be preferably 6-8mscm
-1, present embodiment uses CS02.When the uv-absorbing signal rises to 1.0A
280Begin collector's inosine triphosphate pyrophosphate hydrolase-21.34 when/cm is above, reduce to 0.6A until the uv-absorbing signal
280Till when the maximum volume of/Cm or collection reaches 65 times of column volumes.Chromatography column cleans with CS03 and 04 then, preserves in CS07.
Affinity chromatography: this stepping single step purification human inosine triphosphate pyrophosphate hydrolase-21.34, to remove 45KDa human inosine triphosphate pyrophosphate hydrolase-21.34N-terminal fragment, yeast antigen (if human inosine triphosphate pyrophosphate hydrolase-the 21.34th derives from yeast-leavened recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34) and pigment.Affinity matrix can comprise any type in conjunction with the blue dyestuff of human inosine triphosphate pyrophosphate hydrolase-21.34CibacronO, as Reactive blue 2, the blue HB of Procion, blue agarose, blue acryl and other anthraquinone type compound.This matrix optimization ground is following " the blue agarose of Delta " matrix.This can reduce alkaline stability that matrix produces the degree of blue leach liquor and strengthen matrix to help washing and to reduce phlegm and internal heat former.With commercial matrix phase ratio, further improved matrix is to introduce a spacer groups, 1,4-diaminobutane between dyestuff (Reactive blue 2) and matrix.This is for the wash-out of the pure product of human inosine triphosphate pyrophosphate hydrolase-21.34; The length of spacer groups is suitable.
Ortho position in the Reactive blue structure, a position or para-isomeride or any its mixture all can use.Preferred isomers is ortho position SO
3Type, but be difficult to prepare ideal purity, so use meta-isomer.The preparation of ammonia fourth phthalein one Reactive blue 2 reaches with the whole at least peak of analysis mode high-performance liquid chromatogram determination district and accounts for 98% purity.Also can be by using thick commercial dyestuff, it must purifying ammonia butyryl deutero-dyestuff, or uses pure synthetic dyestuff.In a kind of method in back, the dye substance that begins usefulness should be at least 98% in analysis mode high performance liquid chromatography 280nm mensuration purity.This material is by ACL, and Isle ofMan provides.By heating miscellany to 60 ℃, make Reactive blue 2 and 1, the 4-diaminobutane reacts in water, and the dyestuff of modifying with purifying in the mixture then is as by precipitating.Ammonia butyryl one Reactive blue 2 and matrix coupling then are for example with agarose CL-6B (Pharmacia, the Sweden) coupling of 3-chloro-1-2-propylene oxide activation.See (1971) chromatogram magazines (J.Chromatog) 60 such as Porath, 167-177.The content of the dyestuff of blue agarose (DBA) matrix of this Delta is 50 ± 5mmol/g dry weight preferably.
The use of blue matrix.Present method is used DBA; Height of bed 10-30cm, (present embodiment is 25Cm, and the applied sample amount of post is 7.14g recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34/L matrix to be preferably 20-30cm; (present embodiment is the burnt thin chromatography column volume of 2-9% of working as of 10 ± 1g human inosine triphosphate, is preferably 5-8%, and present embodiment is 7.5% of a column volume to be preferably 8-12g/L.Human inosine triphosphate pyrophosphate hydrolase-21.34 component divides three parts to collect: human inosine triphosphate pyrophosphate hydrolase-21.34 dimer that discards initial a small amount of is until A
280/ Cm rise to pointer completely partially (FSD) 10%; At this moment begin to collect continuously the component that reclaims until reaching completely inclined to one side 90%; Collected then human inosine triphosphate pyrophosphate hydrolase-21.34 is as the primary products component.This is collected continuously until A280 and reduces under the 5% full value partially, and effluent liquid afterwards directly discards again.Reclaim primary products component separate collection.Repeat this step on all raw materials sample to chromatography column.
S-200HR reclaims ultrafiltration: a kind of nominal molecular weight that dams is equal to or less than 30,000, or as present embodiment used 10,000 cellulose-type filter membrane places ultra-filtration equipment, is 20-120g/L human inosine triphosphate pyrophosphate hydrolase-21.34 in order to concentrate recovery component to the retained concentration that compiles; Be preferably 80-110g/L.Filter membrane after the use is pressed method described in the intermediate ultrafiltration and is handled.
The another kind of selection be, in any ultrafiltration step of present method, and nominal dam the polyethers maple of molecular weight 30.000 or the filter membrane that pvdf membrane can replace cellulose-type.This film is provided by Amicon and Millipore.The filter membrane of preferably selecting for use suitable NaOH to store and clean.
S-200HR reclaims the purifying of ultrafiltration retention: from sample on the retention that reclaims the ultrafiltration gained to and the same chromatography column of elementary S-200 purifying, collect the product component from each peak; Mixed with a large amount of elementary product component of collecting previously then.Repeat this step on all raw materials sample to chromatography column.
Anion-exchange chromatography: the purpose in this step is a purifying human inosine triphosphate pyrophosphate hydrolase-21.34 to remove yeast antigen (if human inosine triphosphate pyrophosphate hydrolase-the 21.34th is derived from yeast-leavened recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34) at least and to contain the human inosine triphosphate pyrophosphate hydrolase-21.34 of pigment.The anionresin matrix that present method is used, as QMA-spherosil (SPherosil), DEAE-SPherodex, Q-Hvper D, the DEAE-Mierocrystalline cellulose, (Fractogel is preferably for QAE-Mierocrystalline cellulose or W-DMAE or DEAE classification gel.Matrix with commercial anionresin matrix diethyllaminoethyl sepharose-FF (DEAESepharose-FF) (Phannacia), the height of bed is selected excellent phosphohydrolase-21.34/L matrix according to convenient in the 5-25cm scope).Carry out with the flow rate of 0.3-2.cm/min in steps, be preferably 1.-2.0Cm/min.In the present embodiment 153cm/min.DBA is balance in being derived from the CS01 of CS07; When the ph of effluent liquid in the post was about 9.5, balance was finished.Before the chromatography; The elutriant of SP-FF is regulated with ammonia ... be about 8.5-9.5, preferably PH9.0 goes up sample then to chromatography column.After last sample finishes; Chromatography column is with the specific conductivity 10-30mScm of 1-5 times of volume
-115-25mSm preferably
-1Damping fluid washing to remove impurity, for example use CS12, preferably with 5 times of volumes.Human inosine triphosphate pyrophosphate hydrolase-21.34 usefulness specific conductivity is greater than 100mScm
-1, be preferably 125-165mScm
-1The buffer solution elution of high ionic strength, for example use CS03.As UV signal (A
280/ cm) rise to and begin to collect elutriant when being higher than 0.4 pair, be lower than once more at 0.4 o'clock at signal and stop.Chromatography column washs and is stored in CS07 with CS04 again.
The intermediate ultrafiltration: this step concentrates human inosine triphosphate pyrophosphate hydrolase-21.34 for carrying out gel permeation chromatography.Cellulose-type filter membrane in the ultra-filtration equipment (minimum molecular weight is held back and is lower than or is equivalent to 30,000, for example 10,000) is used for concentrating the DBA elutriant to keep human inosine triphosphate pyrophosphate hydrolase-21.34 concentration 20-120g/L, is preferably 80-100g/L.After the use, filter membrane removes residual protein with CS03 in water or the table 3 or CS05 flushing, and cleans with the sodium hydroxide of 0.1M.Filter membrane can be stored in the sodium hydroxide of 20mM.Gel permeation chromatography.This step purifying human inosine triphosphate pyrophosphate hydrolase-the 21.34th, at Yeast protein (if human inosine triphosphate pyrophosphate hydrolase-the 21.34th derives from the recombinant human human inosine triphosphate pyrophosphate hydrolase-21.34 that yeast is sent out alcohol), the go forward side by side step of row buffering liquid exchange of the human inosine triphosphate pyrophosphate hydrolase of pigment and dimerization-21.34.The gel infiltration matrix of present method commodity in useization is as sephadex G100; G150, G250, Sephacryl S-100, S-200 or S-300, Toyopearl HW50S or sepharose 6 or 12.Preferably, matrix be SePhacryl-200HR (Pharmacia) gel bed height greater than 60cm, be preferably in 90cm (3 * 30cm).Layer folding post balance and with 0.1-1.5cm/min in CS05, the flow rate that is preferably 0.5-1.0cm/min is carried out chromatography, is 0.75cm/min in this enforcement refluence rate; Then when the ph of chromatography column reaches 9.5, with sample on the human inosine triphosphate pyrophosphate hydrolase-21.34 of intermediate ultrafiltration gained to chromatography column.Last sample volume choosing ground approximately mutually is 10-15cm, and as 12.scm, the applied sample amount of post is every liter of matrix 10-60g, is preferably 35 ± 15g/L matrix.Chromatography column is at first reduced to working range with strong damping fluid balance rapidly with pH, as pH4.5-6.0, is preferably about out 5.5 sodium acetate, is example with CS11.Use after the dense damping fluid, adding the S200 elutriant before pillar, use a kind of low conductivity, promptly scope is at 1-4mSm
-1Be preferably 2.5-3.5mSm
-1The solution equilibria chromatography column of CS08 for example.Used linear flow rate is 1.0-8.0cm/min, is preferably 3.0-7.0cm/min, and present embodiment is 4.4cm/min.After last sample finished, chromatography column was with the 5-30mM scope, and preferably the sodium tetraborate solution washing of 15-25mM is for example used CS10.This causes before wash-out human inosine triphosphate pyrophosphate hydrolase-21.34 component, and the impurity of any carbohydrate containing sticks on layer folding post more strongly.With any scope at 10-20mScm
-1The solution wash-out effectively of high ionic strength, preferably use CS06.Work as A
280/ cm reaches at 0.4 o'clock to begin to collect elutriant continuously and reduces to below 0.8 until absorption peak.
Therefore, in the present embodiment; The order of purification step is: cationic exchange, affinity chromatography, ultrafiltration, gel infiltration (adding the ultrafiltration of reclaiming component) and anionresin.
The preparation of embodiment 6 medicaments
After the present invention obtains to contain the preparation of human inosine triphosphate pyrophosphate hydrolase-21.34.Since this material still has activity after freeze-drying, can be fit to make injection.
The injection liquid that contains human inosine triphosphate pyrophosphate hydrolase-21.34 lyophilized powder with physiological saline and/or other suitable diluent preparing.
Some vehicle can be used as the integral part of medicine, such as N.F,USP MANNITOL, lactose, carbohydrate gum, glucose, sucrose and other mixtures.Other some carriers, weighting material and like that can the use.Mixture also can.
According to the present invention, lactose is used as the vehicle of injection drug in the experiment.
In the preparation injection, pH value is set up by conventional acid or alkali.Acid comprises acetic acid etc.Alkali comprises sodium hydroxide etc.Mixture also can.
Also need one or more stablizers such as albumin etc.
Prepare per 20000 ampoules and contain 75 international unit human inosine triphosphate pyrophosphate hydrolases-21.34, method for making is as follows:
An amount of human inosine triphosphate pyrophosphate hydrolase-21.34 lyophilized powder is dissolved in the 700ml cold water, and as necessary, available acetic acid or sodium hydroxide (depending on the circumstances) transfer to 6.2-6.8 with pH value.Pass through 0.2 micron hole filters filter-sterilized then.200 gram lactose are dissolved in the 2 liter cold water, and injection as above adds after the method filter-sterilized in human inosine triphosphate pyrophosphate hydrolase-21.34 solution.Cold water is added to 15 liters, then with the solution five equilibrium to the 0.75ml/ ampoule, and in sterilization lyophilizer freeze-drying.The ampoule of gained contains 75 international unit human inosine triphosphate pyrophosphate hydrolases-21.34 and 10ml lactose like this.
Per ampoule contains 150 international unit human inosine triphosphate pyrophosphate hydrolases-the 21.34th, preferred dose.
According to further preparation example, per ampoule also need contain the stablizer of 1mg human albumin as the vehicle lactose.
Invention has been described for these special cases, but be appreciated that in this external scope in one's power of the present invention to also have many mutabilities.
Sequence table
(1) general information:
(ii) denomination of invention: human inosine triphosphate pyrophosphate hydrolase-21.34-21.34 name and encoding sequence thereof, and the pharmaceutical compound that contains its composition
(iii) sequence number: 6
(2) information of SEQ ID NO:1:
(i) sequence signature:
(A) length: 1085bp
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity
(ii) molecule type: cDNA
( xi ) ：SEQ ID NO：1： 1 CCTGGCCGGAAACTGAGCCGTTCACTTCCGCCACCAGCCGGAAGTTTTCTGTCACTGGAC 61 GCCAAGGAGTTTTCGGTGGCTCAGCTGGGTAACCGGGGATCACCATGGCGGCCTCATTGG121 TGGGGAAGAAGATCGTGTTTGTAACGGGGAACGCCAAGAAGCTGGAGGAGGTCGTTCAGA181 TTCTAGGAGATAAGTTTCCACGCACTTTGGTGGCACAGAAAATTGACCTGCCGGAGTACC241 AGGGGGAGCCGGATGAGATTTCCATACAGAAATGTCAGGAGGCAGTTCGCCAGGTACAGG301 GGCCCGTGCTGGTTGAGGACACTTGTCTGTGCTTCAATGCCCTTGGAGGGCTCCCCGGCC361 CCTACATAAAGTGGTTTCTGGAGAAGTTAAAGCCTGAAGGTCTCCACCAGCTCCTGGCCG421 GGTTCGAGGACAAGTCAGCCTATGCGCTCTGCACGTTTGCACTCAGCACCGGGGACCCAA481 GCCAGCCCGTGCGCCTGTTCAGGGGCCGGACCTCGGGCCGGATCGTGGCACCCAGAGGCT541 GCCAGGACTTTGGCTGGGACCCCTGCTTTCAGCCTGATGGATATGAGCAGACGTACGCAG601 AGATGCCTAAGGCGGAGAAGAACGCTGTCTCCCATCGCTTCCGGGCCCTGCTGGAGCTGC661 AGGAGTACTTTGGCAGTTTGGCAGCTTGACTTCTGCAGCTGGAGGAGGCCCCTCAGGCCG 721 GGGATCTGGGGAGGGCTAGCCCAAAACCTCCCGCATCGGGCAGGCACCCCCTGAAGTACT 781 TCCTTCAGGGTTTCCCCTTTGTGAGGGTGTCAAGTAGCCTCACCGGCCTGTCTGGAGGAG 841 CAGCTGGCTCTGCTCTGAGAAACTCTGGCAAGTGGACGCCATTCTCTTGCCCTTAGGATT 901 CACTGCTCTCTCCTACAGCCGCCAGGCCTGGGGTCCTGAAAGGACCTTGGGTGGTAAAGC 961 TGTACTTGGTGGGAGTGAGGGCGTGGGGAGGAACCATGCAAATCGCCTTCCATGGTTTTT1021 AAATGCAGTAAATAACATTTCTGGATGAGACTTGTTTCCAAAATAAACCAGCTATATCTG1081 TTCCGAAAAAAAAAAAAA ( 3 ) SEQ ID NO：2：
(i) sequence signature:
(A) length: 194 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ii) molecule type: polypeptide
( xi ) ：SEQ ID NO：2： 1 Met Ala Ala Ser Leu Val Gly Lys Lys Ile Val Phe Val Thr Gly 16 Asn Ala Lys Lys Leu Glu Glu Val Val Gln Ile Leu Gly Asp Lys 31 Phe Pro Arg Thr Leu Val Ala Gln Lys Ile Asp Leu Pro Glu Tyr 46 Gln Gly Glu Pro Asp Glu Ile Ser Ile Gln Lys Cys Gln Glu Ala 61 Val Arg Gln Val Gln Gly Pro Val Leu Val Glu Asp Thr Cys Leu 76 Cys Phe Asn Ala Leu Gly Gly Leu Pro Gly Pro Tyr Ile Lys Trp 91 Phe Leu Glu Lys Leu Lys Pro Glu Gly Leu His Gln Leu Leu Ala106 Gly Phe Glu Asp Lys Ser Ala Tyr Ala Leu Cys Thr Phe Ala Leu121 Ser Thr Gly Asp Pro Ser Gln Pro Val Arg Leu Phe Arg Gly Arg136 Thr Ser Gly Arg Ile Val Ala Pro Arg Gly Cys Gln Asp Phe Gly151 Trp Asp Pro Cys Phe Gln Pro Asp Gly Tyr Glu Gln Thr Tyr Ala166 Glu Met Pro Lys Ala Glu Lys Asn Ala Val Ser His Arg Phe Arg181 Ala Leu Leu Glu Leu Gln Glu Tyr Phe Gly Ser Leu Ala Ala ( 4 ) SEQ ID NO：3 ( i )
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:3:CCTGGCCGGAAACTGAGCCGTTCA (5) SEQ ID NO:4
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity is molecule type (ii): oligonucleotide (xi) sequence description: information (i) sequence signature of SEQ ID NO:4:TTTTTTTTTTTTTCGGAACAGATA (6) SEQ ID NO:5
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide
(xi) sequence description: the information of SEQ ID NO:5:CCCCATATGATGGCGGCCTCATTGGTGGGGAAG (7) SEQ ID NO:6
(i) sequence signature
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: SEQ ID NO:6:CATGGATCCTCAAGCTGCCAAACTGCCAAAGTA
Claims (13)
1, a kind of isolated polypeptide-human inosine triphosphate pyrophosphate hydrolase-21.34 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.
4. polypeptide as claimed in claim 1 contains in every milligram of lyophilized powder under such specification of general 6200 international unit human inosine triphosphate pyrophosphate hydrolases-21.34, has distinctive activity.
5. the pharmaceutical compound that can treat relevant and figuration body pharmaceutically with the described polypeptide of claim 1.
6. pharmaceutical compound as claimed in claim 5, its figuration body is a lactose.
7. pharmaceutical compound as claimed in claim 5 contains the human inosine triphosphate pyrophosphate hydrolase-21.34 of 75 international unit in its measure unit.
8. polypeptide as claimed in claim 1 contains in every milligram of lyophilized powder under such specification of 6200 international unit human inosine triphosphate pyrophosphate hydrolases-21.34, has distinctive activity.
9. the intramuscularly agent of human inosine triphosphate pyrophosphate hydrolase-21.34, the human inosine triphosphate pyrophosphate hydrolase-21.34 that wherein contains 0.05-70%, in the time of suitably, can be used as the salt that forms with bronsted lowry acids and bases bronsted lowry or as prodrug, dosage form is water-based or oily suspensions.
10. the intramuscularly agent according to claim 9 is that human inosine triphosphate pyrophosphate hydrolase-21.34 particulate size for 0.5-150 μ m, is preferably 4-40 μ m.
11. according to it is characterized in that of the intramuscularly agent of claim 9: their osmolality (osmolality) is 200-900 m osmol/kg, preferably 260-390 m osmol/kg.
12., it is characterized in that they contain the human inosine triphosphate pyrophosphate hydrolase of 2.5-50% (weight)-21.34 according to claim 9,10,11 intramuscularly agent.
13. according to the intramuscularly agent of claim 9 application in treatment human body and animal body method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01112773 CN1382796A (en) | 2001-04-26 | 2001-04-26 | Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01112773 CN1382796A (en) | 2001-04-26 | 2001-04-26 | Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1382796A true CN1382796A (en) | 2002-12-04 |
Family
ID=4659528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01112773 Pending CN1382796A (en) | 2001-04-26 | 2001-04-26 | Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1382796A (en) |
-
2001
- 2001-04-26 CN CN 01112773 patent/CN1382796A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498959B2 (en) | Anti-CGRP antibody formulation | |
| CN100408095C (en) | Multivalent DTP-POLID vaccines | |
| CN1089344C (en) | Inhibitor of stem cell proliferation and uses thereof | |
| AU2012326082B2 (en) | Etanercept formulations stabilized with xylitol | |
| EA014232B1 (en) | Stable protein formulations | |
| EA011390B1 (en) | Muteins of fibroblast growth factor 21 | |
| CA2256410C (en) | Stable pharmaceutical composition of bdnf | |
| JP2005508848A6 (en) | Application of consensus interferon as an inhibitor of hepatitis B surface antigen and e antigen | |
| JP2005508848A (en) | Application of consensus interferon as an inhibitor of hepatitis B surface antigen and e antigen | |
| CN107709350A (en) | Purifying and/or the method for inactivation of virus | |
| CA1283048C (en) | Therapeutic agent for treating hematopoietic diseases | |
| CN103611162B (en) | Human blood coagulation factors VIII freeze drying protectant and preparation method thereof | |
| CN1382796A (en) | Polypeptide-human inosine triphosphate pyrophosphohydrolase-21.34 and pharmaceutic compound containing it | |
| BR112012020934B1 (en) | PROCESS FOR PURIFICATION OF RECOMBINANT HUMAN ALPHA MANNOSALS ALPHA MANNOSIS FROM A CELL CULTURE, COMPOSITION, FED BATCH PROCESS OR CONTINUOUS PRODUCTION OF RECOMBINANT HUMAN ALPHA MANNOSALS AND USE OF COMPOSITION | |
| EP0591605A2 (en) | Method for suppressing coloring of human serum albumin | |
| CN1382798A (en) | Polypeptide-diphosphoadenosine ribodiphosphatase-38.5 and pharmaceutical compound containing it | |
| CN114539426A (en) | Fusion protein containing interferon alpha, recombinant strain expressing fusion protein and preparation method thereof | |
| JP2023522423A (en) | Interferon alpha 2 variants and their uses | |
| CN109467597B (en) | Novel interferon and preparation method, composition and application thereof | |
| JPH07503705A (en) | Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof | |
| DK152058B (en) | PROCEDURE FOR THE PREPARATION OF AN INSULIN-SECRETING SUBSTANCE | |
| EP3154597B1 (en) | Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents | |
| RU2681413C9 (en) | WAYS OF OBTAINING A NEW GENERATION OF SAFE WITH THE BIOLOGICAL POINT OF VIEW OF KLH PRODUCTS USED FOR CANCER TREATMENT, TO DEVELOP CONCURNED THERAPEUTIC VACCINES AND AS A PROMOTION OF ACTUATED THERAPEUTIC VACCINES AND IN THE QUALITY OF STIMULATING THERAPY. | |
| EP0420743B1 (en) | Vaccine protecting against porcine hemophilus | |
| WO2024056028A1 (en) | Analgesic polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |